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Abstract
Thyroid hormone (TH) disease is common among older adults and is associated with cognitive 
impairment. However, pathologic correlates are not well understood. We studied pathologic and 
clinical factors associated with hypothyroidism, the most common form of TH disease, in research 
subjects seen annually for clinical evaluations at U.S. Alzheimer’s Disease Centers. Thyroid 
disease and treatment status were assessed during clinician interviews. Among autopsied subjects, 
there were 555 participants with treated hypothyroidism and 2,146 with no known thyroid disease; 
hypothyroidism was associated with severe atherosclerosis (OR=1.35 95% CI: 1.02, 1.79) but not 
Alzheimer’s disease (AD) pathologies (amyloid plaques or neurofibrillary tangles). Among 
participants that did not come to autopsy (4,598 with treated hypothyroidism and 20,045 without 
known TH disease), hypercholesterolemia and cerebrovascular disease (stroke and transient 
ischemic attack) were associated with hypothyroidism, complementing findings in the smaller 
autopsy sample. This is the first large-scale evaluation of neuropathologic concomitants of 
hypothyroidism in aged individuals. Clinical hypothyroidism was prevalent (~25% of individuals 
studied) and was associated with cerebrovascular disease but not AD-type neuropathology.
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Introduction
The pathologic sequelae of thyroid hormone (TH) dysregulation in the aged human brain are 
incompletely understood. Among the elderly, hypothyroidism is reported in up to 30% of 
research participants and hyperthyroidism in up to 10% (see (Canaris et al., 2000; Empson et 
al., 2007; Sawin et al., 1985; Vanderpump, 2011; Verburg et al., 2017)), and both clinical 
hypothyroidism and hyperthyroidism are associated with substantial morbidity and mortality 
(Gencer et al., 2013; Grossman et al., 2016; Imaizumi et al., 2004; Tan et al., 2008; Yeap et 
al., 2013).
TH is an evolutionarily ancient hormone with strong impact on human cellular metabolism, 
brain development, and cardiovascular health (Boelaert and Franklyn, 2005; Maenhaut et al., 
2000). TH dysregulation in advanced age is also associated with risk for dementia (Chaker et 
al., 2016c; Mafrica and Fodale, 2008; Sampaolo et al., 2005; Tan and Vasan, 2009); a 
PubMed search using terms “(thyroid or thyroxine) and (Alzheimer’s or dementia)” returns 
>500 published papers. The literature indicates a complicated relationship between TH and 
dementia risk. Hyperthyroidism is usually more strongly associated with cognitive decline, 
although some reports indicate that hypothyroidism also is a risk factor for dementia 
(Akintola et al., 2015; Chaker et al., 2016c; Moon, 2016; Moon et al., 2014; Pasqualetti et 
al., 2015; Rieben et al., 2016; Tan and Vasan, 2009; van Osch et al., 2004; Wu et al., 2016; 
Yeap et al., 2012). These are important questions, particularly since the elderly population is 
expanding and pharmacological manipulation of TH levels provide a possible disease-
modifying strategy.
Perhaps due to the many relevant covariates that constitute formidable potential 
experimental confounders, there currently is no consensus as to the mechanism(s) 
underlying the link(s) between TH disease and dementia. In terms of specific disease 
processes, lack of TH in utero and in early life causes severe cognitive impairment (a 
component of “cretinism”), with extensive white matter pathology (Rosman, 1972). Some 
studies suggest that hypothyroidism may induce structural changes in the hippocampus 
(Cooke GE, 2014; Koromilas C, 2010). However, much is still unknown about how TH 
dysregulation is correlated with brain pathologies in old age. TH dysregulation has been 
implicated in or comorbid with cardiovascular disease, stroke, hippocampal sclerosis of 
aging/cerebral age-related TDP-43 with sclerosis (CARTS), autoimmune disease(s), and, 
possibly, Alzheimer’s disease (AD) (Chaker et al., 2017; Chaker et al., 2016b; Collet et al., 
2012; de Jong et al., 2009; Frohlich and Wahl, 2017; Mafrica and Fodale, 2008; Nelson et 
al., 2016a; Squizzato et al., 2005; Tan and Vasan, 2009; Zhang et al., 2017). Prospective 
studies are few in number and lack pathologic endpoints, so cohorts that follow patients to 
autopsy are required to provide needed insights into how TH disease affects the aged brain.
The objective of this study was to evaluate associations between common cerebrovascular 
and neurodegenerative pathologies and clinical hypothyroidism (as operationalized by 
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clinician interview during a clinical examination). We analyzed National Alzheimer’s 
Coordinating Center (NACC) data gathered from U.S. Alzheimer’s Disease Centers (ADCs). 
We focused on treated hypothyroidism since this was by far the most common clinical TH 
syndrome in this sample. Because hypothyroidism previously has been associated with 
cardiovascular risk factors (Abreu et al., 2017; Delpont et al., 2016; Imaizumi et al., 2004; 
Pasqualetti et al., 2015), we hypothesized that hypothyroidism would be associated with 
cerebrovascular pathology. As a secondary objective, we conducted a separate analysis of 
the relationship between hypothyroidism and clinical cardiovascular disease and risk factors 
in a complementary sample of non-autopsied participants.
Methods
Data sources and study populations
Data were obtained from NACC’s Uniform Data Set (UDS) on participants who had been 
prospectively evaluated at one of 34 past and present U.S. ADCs between September 2005 
and December 2016. Participants were evaluated annually at an ADC using a standardized 
clinical protocol (Beekly DL, 2004, 2007). Participants enrolled with any level of cognition 
from normal to demented. Individual ADCs recruit and enroll participants according to their 
own protocols. UDS data were collected annually via trained clinicians or interviewers 
through in-person office visits at each ADC. At each visit, subjects received physical and 
neurological examinations, plus a battery of neuropsychological assessments. 
Neuropathology data were collected from neuropathologists based on autopsy results for 
subjects who died and had consented to autopsy evaluation at an ADC. Individual ADCs 
received institutional review board approval and written informed consent was obtained 
from all participants and their study co-participants.
The current analyses focused on two samples: 1.) UDS participants who had been autopsied 
(autopsy sample) and 2.) UDS participants who were still alive or who had died but had not 
been autopsied (clinic sample). Participants were excluded from the autopsy sample if they 
had 1.) age of death younger than 55 years (due to small numbers); 2.) rare disease(s) such 
as Down’s syndrome, prion disease, autosomal dominant genetic diseases (i.e. early onset 
AD), or FTLD; 3.) reported use of hyperthyroid medication at any visit; or, 4.) were missing 
information on thyroid disease, demographics, health history or common neuropathologies. 
Participants were excluded from the clinic sample if they had 1.) age at baseline younger 
than 55 years; 2.) reported use of hyperthyroid medication at any visit; or, 3.) were missing 
information on thyroid disease, demographics, or health history. Figure 1 shows the study 
sample flow and distribution of concurrent thyroid disease and medication use.
Among 2,847 autopsied participants who met inclusion criteria, 25% had a history of thyroid 
disease and/or were taking hypothyroid medications, while in the clinic sample 22% of 
26,930 eligible participants had a history of thyroid disease or hypothyroid medication use. 
Most participants with thyroid disease and hypothyroid treatment reported active thyroid 
disease (93% in the autopsy sample, 82% in the clinical sample). The majority of persons 
who reported thyroid disease without hypothyroid treatment had inactive thyroid disease 
(62% of the autopsy sample and 46% of the clinical sample). Due to low numbers and 
potential differences in thyroid disease status, we excluded subjects who reported thyroid 
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disease without hypothyroid treatment or reported no thyroid disease but had hypothyroid 
treatment. The primary analyses focused on participants with thyroid disease and 
hypothyroid medication use compared to those who did not report thyroid disease or 
medication use (Figure 1).
Thyroid disease and treatment
History of thyroid disease was assessed at each UDS visit based on clinician interview from 
2005 to 2014, and was recorded as recent, remote, or not present. For follow-up participant 
visits after 2015, thyroid disease diagnosis (yes, no) was based on clinician assessment. In 
the current analysis, we categorized participants based on whether they had thyroid disease 
present at one or more visits. Reported use of hyperthyroid medications (methimazole, 
propylthiouracil, and sodium iodide I-131) or hypothyroid medications (e.g. levothyroxine, 
thyroid desiccated, liothyronine, and liotrix) was recorded at each UDS visit. Participants 
were categorized into 4 groups based on reported thyroid disease status and hypothyroid 
medication status across followup: thyroid disease with hypothyroid treatment (TH+T+), no 
thyroid disease and no treatment (TH−T−), thyroid disease without hypothyroid treatment 
(TH+T−), and thyroid disease not reported but hypothyroid medication reported (TH−T+).
Covariates
Demographic characteristics included age, sex, education, race/ethnicity, and ADC. History 
of comorbidities, such as depression, vascular risk factors, diabetes, cardiovascular disease, 
and stroke were evaluated during each clinical visit. APOE genotyping was performed on 
consenting participants. APOE ε4 allele status was classified as at least one or none. 
Assessment of cognitive status was made at each visit; dementia diagnosis was made by 
either a single clinician or consensus group of clinicians, after a review of all evaluation 
information available. Clinical impairment was quantified at each study visit with the 
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)(JC, 1993), a composite measure 
of the overall level of cognitive impairment and functional disability that is based on clinical 
judgment and study co-participant report.
Neuropathological Features
ADCs followed consensus-based guidelines but conducted neuropathologic assessments 
according to center-specific protocols. Neuropathologists used a standardized form and 
results were uploaded to the NACC database. Operationalization of AD neuropathologic 
changes (ADNC) included Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) stages of Aβ neuritic plaque densities (none, sparse, moderate, frequent) (Mirra 
SS, 1991) and Braak stages for tau neurofibrillary pathology (0, I–III, IV, V, VI) (Braak et 
al., 2006). ADNC was defined regardless of an individual’s documented cognitive status. 
ADNC as defined by new NIA-Alzheimer’s Association criteria (Hyman et al., 2012) also 
includes Thal staging (Beekly et al., 2004; Thal DR, 2002) for Aβ plaques, however this was 
not available for most participants before 2014. Presence of cortical microinfarcts (infarcts 
in the cortex only seen microscopically) and/or gross infarcts (small or large artery infarcts 
that are visible at the time of autopsy) were recorded regardless of age. Cerebral amyloid 
angiopathy, atherosclerosis, and arteriolosclerosis were classified as none, mild, moderate, 
or severe. Assessment for Lewy bodies followed recognized guidelines (McKeith IG, 2005). 
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Lewy body disease (LBD) was defined as presence of Lewy bodies in any brain region 
examined. Subtypes of LBD were classified as none, brainstem predominant, limbic 
(transitional), neocortical (diffuse), or other or unknown region. Hippocampal sclerosis was 
categorized as present based on neuropathologic diagnosis (forms prior to 2014) or if 
recorded as unilateral, bilateral, or laterality unknown (forms after 2014).
Statistical Analyses
Characteristics of participants were described stratified by thyroid disease status. Kruskal-
Wallis and χ2 tests and tests evaluated whether characteristics differed in distribution 
between those with and without treated hypothyroidism (TH+T+ vs TH−T−). Multivariable 
logistic regression models assessed associations between hypothyroidism and 
neuropathologic characteristics. Models included adjustment for demographics (age at death, 
sex, race, education) and clinical characteristics (CDR-SB at last visit and history of the 
following comorbidities: hypertension, hypercholesterolemia, diabetes, smoking, atrial 
fibrillation, heart attack, congestive heart failure). Generalized estimating equations were 
used to account for clustering of participant within ADCs and robust standard errors were 
calculated. Several sensitivity analyses were conducted. First, we examined the effect of 
including all participants with reported thyroid disease or hypothyroid medications. Next, 
we tested the effects of additional adjustment for APOE ε4 allele and BMI.
We further explored the associations between thyroid disease with vascular disease in both 
the autopsy and clinical samples. In the autopsy sample, associations were assessed between 
vascular risk factors, cardiovascular disease, clinical cerebrovascular disease, and 
cerebrovascular pathologies. Because criteria for pathologies became more standardized in 
NACC forms after 2014, these analyses were stratified based on those who had died 2005–
2013 and those who had died after 2014 (no overlap in the samples). In the clinical sample 
we explored associations between vascular risk factors, cardiovascular disease, clinical 
cerebrovascular disease and hypothyroidism in those with and without dementia at baseline.
All tests were two-sided with α = 0.05. Analyses were conducted using R (version 3.2.1, R 
Core Team, 2015).
RESULTS
There were 555 autopsied participants with treated hypothyroidism and 2,146 without 
known thyroid disease. These participants were followed an average of 2.8 years (SD: 2.3 
years) and a majority were demented by their last visit (78%). There were 4,598 clinical 
participants with treated hypothyroidism and 20,045 without thyroid disease, who were 
followed an average of 2.8 years (SD: 3.0 years) and 32% were demented at the time of 
enrollment.
Participants with thyroid disease were more likely to be older, female, Caucasian, and to 
have a history of vascular risk factors and disease (Table 1). Predicted probability of thyroid 
disease by age at death is shown in Figure 2A for males and females. Before controlling for 
other factors, participants with thyroid disease were less likely to be demented (Table 1), and 
were less likely to have high ADNC or LBD (Table 2); in terms of cerebrovascular 
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pathologies, gross infarcts and atherosclerosis were more common in those with reported 
thyroid disease (Table 2).
Pathologies and hypothyroidism
In multivariable logistic regression models, severe atherosclerosis was associated with a 
35% higher odds of hypothyroidism after adjustment for potential confounders (Table 3). By 
contrast, neither CERAD neuritic plaque score nor Braak NFT Stage for neurofibrillary 
tangles were associated with hypothyroidism in this model (Table 3). Findings did not 
change substantially with adjustment for APOE ε4 allele or BMI, but missing data was 
greater, so we present findings from primary models. There was a trend for lower prevalence 
of LBD in those with hypothyroidism; this trend was observed in both men and women 
(Figure 2B). Among 630 participants aged >85 years at death and without severe ADNC 
(e.g. Braak Stage 0–IV) there was a trend for HS pathology to be inversely associated with 
hypothyroidism (OR: 0.51; 95% CI: 0.25, 1.03; p=0.06).
Clinical vascular disease and hypothyroidism
Hypercholesterolemia, atrial fibrillation, and cerebrovascular disease were associated with 
hypothyroidism in subsamples. Only atrial fibrillation was associated with hypothyroidism 
in those autopsied 2005–2014 although odds ratios were similar to results from those 
autopsied after 2014 (Table 4). Among participants who were evaluated since 2014 (with a 
newer form), hypercholesterolemia and gross infarcts were significantly associated with 
hypothyroidism but the associations with atherosclerosis were no longer significant. 
Additionally, in the clinical sample, hypercholesterolemia and diabetes were associated with 
hypothyroidism in those without dementia at baseline (Table 5). In those with dementia, 
cerebrovascular disease was also associated with hypothyroidism in those with dementia 
(Table 5; Figure 2C), with increased ORs for atrial fibrillation and congestive heart failure.
Discussion
In the large NACC data set, clinical hypothyroidism was associated with cardiovascular and 
cerebrovascular diseases. Hypothyroidism was substantially more common in females than 
males. Hypothyroidism was associated with severe atherosclerosis pathology and with gross 
infarcts in autopsied participants. In both the autopsy sample and the clinical (no autopsy) 
sample, hypothyroidism was associated with vascular disease, especially 
hypercholesterolemia. These results provide some new directions for studying two of the 
prevalent conditions linked to aging—dementia and hypothyroidism.
The strongest associations in this study were between hypothyroidism and cerebrovascular/
cardiovascular parameters and pathologies. There have been prior reports that have broadly 
similar findings: hypothyroidism has been associated with hypercholesterolemia, atrial 
fibrillation, diabetes, and, ultimately, cerebrovascular disease that is perhaps independent of 
other known cardiovascular risk factors (Abreu et al., 2017; Chaker et al., 2016a; Delitala et 
al., 2017; van Tienhoven-Wind and Dullaart, 2015). Importantly, TH replacement can lead to 
improved cardiovascular risk factors (Abreu et al., 2017; Adamarczuk-Janczyszyn et al., 
2016). Our study of autopsied and non-autopsied participants enabled some important new 
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findings to provide insights into the pathogenetic mechanisms involved. Specifically, 
autopsied persons with treated hypothyroidism tended to have higher risk for severe 
atherosclerosis in the Circle of Willis, and also gross infarcts on pathological examination of 
the brains in the more recent autopsy subset. Brain infarct data collection became more 
standardized after 2014, which may account for the association between gross infarcts and 
treated hypothyroidism in the more recent autopsies; including higher quality infarct data 
may also have attenuated the finding with atherosclerosis in the same model. However, there 
may also be differences in sample characteristics by time-period as history of atrial 
fibrillation was associated with hypothyroidism in those autopsied 2005–2013 while 
hypercholesterolemia was associated with autopsies from 2014. In a prior study of carotid 
plaques detected with ultrasound, plaque burden was associated with low, but not high, 
thyroid stimulating hormone values (Dorr et al., 2008), while a separate study found that 
“subclinical” hypothyroidism was associated with higher carotid intima-media thickness 
(Peixoto de Miranda et al., 2016). It is challenging to adequately control for all the various 
possible confounders related to cardiovascular risk and hypothyroidism. For example, the 
factors that contribute to risk for incident stroke may not be the same as those that alter the 
brain’s compensatory changes afterward (see (Chaker et al., 2016a; Delpont et al., 2016)). 
Future prospective studies will be required to tease out the specific biologic mechanisms. 
However, these data provide strong indication of an association between treated 
hypothyroidism and large-vessel cerebrovascular disease. Our findings that 
hypercholesterolemia, atrial fibrillation, and stroke/TIA were also associated with 
hypothyroidism in the clinical sample (non-autopsied sample) also lend further support to 
this hypothesis.
The correlations between hypothyroidism and neurodegenerative diseases were weaker than 
those related to cerebrovascular disease. We evaluated three main types of pathology-defined 
neurodegenerative diseases in this study: ADNC, LBD, and HS (a key pathology in Cerebral 
Age-Related TDP-43 With Sclerosis [CARTS]). Our study found no evidence of an 
association between hypothyroidism and AD-type amyloid plaques or neurofibrillary 
tangles. When other parameters were controlled for in regression-based models, there was 
no trend for “protective” or “harmful” effects of hypothyroidism. By contrast, there did seem 
to be a trend for LBD pathology to be inversely associated with treated hypothyroidism. 
Although there seems to be a potential of confounding due to sexual dimorphism (men have 
higher risk for DLB (Nelson et al., 2010), and, as underscored by the current study, women 
have higher risk for hypothyroidism), this association did not seem to be biasing the results: 
both men and women that were treated for hypothyroidism showed a trend for lower risk for 
LBD pathology. Age is also an important potential confounder since, on average, the persons 
with hypothyroidism in this dataset were somewhat older than those without diagnosed 
thyroid disease. However, to the best of our knowledge, this is the first evidence of a link 
between TH disease and LBD, and merits further study.
We also assessed the potential association between HS pathology and hypothyroidism. We 
had previously found genetic evidence of risk, and also CSF findings, linking TH 
dysregulation and HS-Aging/CARTS pathology (Nelson et al., 2016a; Nelson et al., 2016b). 
In the current study, we found no evidence of a robust association between hypothyroidism 
and HS pathology. We note that there was a trend for lower prevalence of HS among those 
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with treated hypothyroidism (p=0.06) in a subsample (the oldest-old without high Braak 
NFT Stages); however, there was a trend for slightly increased prevalence of HS pathology 
among those with treated hypothyroidism overall (p=0.2). This merits further study given 
the many sources of potential confounding (e.g., many false-negative HS cases on 
pathology) in this study, and the lack of substantial numbers of hyperthyroid cases in this 
sample.
There are limitations and caveats relevant to these analyses. We had no measure of 
“subclinical” thyroid hormone disease (Grossman et al., 2016; Surks et al., 2004; Visser et 
al., 2013); and levothyroxine use can lead to “over-replacement” (iatrogenic 
hyperthyroidism), which can be symptomatic with anxiety and atrial fibrillation. Thus a 
person treated for hypothyroidism (usually with levothyroxine) may be considered to 
represent an example of hypothyroidism, and/or has brain changes secondary to the hormone 
replacing drug, and/or is impacted by an underlying (possibly autoimmune) condition that 
manifests with hypothyroidism and with other systemic and/or neurologic effects. There is 
some evidence that persons treated with levothyroxine often maintain above-average thyroid 
stimulating levels (Razvi et al., 2016), and thus are presumably still ‘hypothyroid’ in a 
clinico-biologic sense, but, it is unclear how this may have affected our findings. In the 
autopsy sample, participants with thyroid disease tended to be older, less likely to be 
demented, and were far more likely to be female. These observations are interesting in their 
own right. While we adjusted for these factors in regression models, it is important to keep 
these potential confounders in mind. “Dementia research clinics”, as represented by most 
U.S. ADCs, follow samples that differ from a broader population, drawing from a sample 
comprising mostly Caucasian, relatively high socioeconomic status persons with relatively 
high risk for clinical AD – not a population-based sample.
Despite those concerns, the NACC database represents one of the world’s largest and 
highest-quality multicenter databases, with both detailed clinical (including medication use 
and cognitive status) and pathological information. The database has been extensively 
audited. Our findings may thus have more generalizable significance. In addition, we 
conducted additional secondary and sensitivity analyses to inform generalizability of our 
results; findings were similar between autopsied and non-autopsied participants as well as 
those autopsied with more recent standardized data collection forms vs. earlier forms.
In summary, our analyses highlight an association between hypothyroidism and risk for 
cerebrovascular disease, but not AD pathology. Hypothyroidism was associated with severe 
atherosclerosis pathology and with gross infarcts in a subset of participants. In both the 
autopsy sample and the clinical sample, hypothyroidism was associated with 
hypercholesterolemia and cerebrovascular disease. In the clinical sample, hypothyroidism 
was associated with stroke and transient ischemic attacks among those with dementia at 
baseline. Approximately one-quarter of all the research subjects reported some type of TH-
linked disease. These results indicate that further study on the link between causes of 
dementia and thyroid disease is merited to provide guidance for clinicians to optimize 
management of TH levels in the elderly.
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Highlights
• Thyroid hormone disease is common among the elderly but pathologic 
correlates are not known.
• In a large sample (National Alzheimer’s Coordinating Center, comprising 
almost 30,000 total research subjects), approximately ¼ of individuals 
reported treated hypothyroidism.
• Among both autopsied and non-autopsied individuals, treated hypothyroidism 
was associated with cerebrovascular disease and stroke.
• Treated hypothyroidism was not associated with altered Alzheimer’s disease 
pathology in this Sample.
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Figure 1. Study sample flow chart
FTLD, frontotemporal lobar degeneration; TH; Thyroid disease, T, Hypothyroid treatment; 
NACC, National Alzheimer’s Coordinating Center; UDS: Uniform Data Set. Primary 
Analyses focus on comparisons between TH−T− and TH−T+ participants.
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Figure 2. Study of associations between treated hypothyroidism (TH+T+) and various 
parameters across the aging spectrum
a. Probability of TH+T+ status by age and sex. Predicted probabilities shown based on 
logistic regression of TH+T+ with sex and age as predictors in the clinical sample. Across 
all ages, females are far more likely than males to be TH+T+ in this sample (P<0.001). b. 
Probability of Lewy body disease (LBD) and by age, stratified by TH+T+ status and sex. 
Predicted probabilities shown based on a logistic regression of LBD with age, sex, and 
thyroid disease status as predictors in the autopsy sample. The trend for an association 
between LBD and TH+T+ was borderline significant (P=0.06) but the pattern was strikingly 
similar for both sexes. c. Probability of TH+T+ by history of stroke or transient ischemic 
attack (TIA) in the clinical sample with dementia. Predicted probabilities shown based on 
logistic regression of TH+T+ with age at baseline, sex, non-white race, education, Clinical 
Dementia Rating sum of boxes score at baseline, depression, follow-up duration, and history 
of vascular risk factors or cardiovascular disease as predictors. There was a consistent trend 
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across the aging spectrum for more stroke/TIA in persons with TH+T+ status, including 
after cardiovascular risk factors were included in the model (P=0.015).
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Table 2
Pathologic characteristics of participants with and without treated thyroid disease
Autopsy Sample
Pathologic Characteristicsa TH−T− (n=2,186) TH+T+ (n=570) Pb
Frequent Neuritic Plaques 1168 (54.4) 261 (47) 0.002
Braak NFT Stage V–VI 1307 (60.9) 290 (52.3) < 0.001
Lewy body disease 846 (39.4) 161 (29) < 0.001
Gross infarcts 474 (22.1) 153 (27.6) 0.008
Cortical microinfarcts 348 (16.2) 95 (17.1) 0.655
Severe CAA 259 (12.3) 55 (10.1) 0.176
Severe Atherosclerosis 251 (11.7) 97 (17.5) < 0.001
Severe Arteriolosclerosis 240 (12.8) 69 (14) 0.526
Hippocampal Sclerosis 183 (8.5) 57 (10.3) 0.229
Abbreviations: CAA, cerebral amyloid angiopathy; NFT, neurofibrillary tangle; TH−T−, no thyroid disease and no treatment; TH+T+, thyroid 
disease with hypothyroid treatment
aValues are represented as N(%). Missing data: CAA=42 (1.6%), arteriolosclerosis = 336 (12.4%).
b
Based on χ2
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Table 3
Associations between neuropathologic features and treated (TH+T+) thyroid disease (n=2,701)a
Thyroid Disease
OR 95% CI P
Neuritic Plaque Density
 None 1.00 — —
 Sparse 0.97 0.67 1.39 0.85
 Moderate 0.98 0.68 1.41 0.91
 Frequent 1.02 0.69 1.51 0.91
Braak NFT Stage
 Braak 0–III 1.00 — —
 Braak IV 0.86 0.63 1.19 0.36
 Braak V 0.85 0.60 1.20 0.34
Braak VI 0.86 0.61 1.22 0.40
Lewy body disease 0.82 0.66 1.03 0.08
Gross infarcts 0.99 0.78 1.26 0.97
Microinfarcts 0.90 0.68 1.20 0.48
Severe Atherosclerosis 1.35 1.02 1.79 0.03
Hippocampal Sclerosis 1.14 0.81 1.60 0.45
Abbreviations: CI, Confidence Interval; NFT, neurofibrillary tangle; OR, Odds Ratio
a
Based on multivariable logistic regression model adjusted for age at death, sex, nonwhite race, education, Clinical Dementia Rating sum of boxes 
score at last visit, hypertension, hypercholesterolemia, smoking, diabetes, atrial fibrillation, heart attack, congestive heart failure, and interval 
between last visit and death
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